Compare Enveric Biosciences Inc (ENVB) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kohl's Corporation — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Kohl's Corporation trades at $20.35 (market cap $2.28B). The key difference: Kohl's Corporation is far larger — about 335.3× Enveric Biosciences Inc's market cap, and Kohl's Corporation pays a 2.49% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Kohl's Corporation for 48 Days on average.
| ENVB | KSS | |
|---|---|---|
Market Cap | $6.80M | $2.28B |
Volume | 64,867 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $24.71 |
52-Week Low | $1.27 | $11.72 |
Typical Hold Time | 14 Days | 48 Days |
Enterprise Value | -$1.49M | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and a new merchandising appointment signal operational improvements. Revenue trends show stabilization after several quarters of decline, with 2026 projections indicating potential margin recovery.
KSS presents a value opportunity with deep discount to sector peers, though persistent sales declines and competitive pressures remain headwinds. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism amid turnaround execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
